An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02271347

Acronym

CMX

Enrollment

Registered

2014-10-22

Start date

2014-10-31

Completion date

2015-01-31

Last updated

2015-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ebola Virus

Brief summary

The purpose of this study is to assess the safety and tolerability of Brincidofovir (BCV) when administered as an initial 200mg dose followed by 100mg twice weekly (BIW) for a total of 5 doses.

Interventions

DRUGCMX001

CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

2 Months to 75 Years

Healthy volunteers

Inclusion criteria

* Positive for Ebola virus RNA in plasma * Subject must be able to ingest, absorb, and tolerate oral medication * Subject must be willing to use adequate contraception during their participation

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerability.	4 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026